edoc

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Finckh, A. and Ciurea, A. and Brulhart, L. and Möller, B. and Walker, U. A. and Courvoisier, D. and Kyburz, D. and Dudler, J. and Gabay, C. and Arthritis, . (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Annals of the rheumatic diseases, Vol. 69, H. 2. pp. 387-393.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003965

Downloads: Statistics Overview

Abstract

Patients with rheumatoid arthritis (RA) with an inadequate response to TNF antagonists (aTNFs) may switch to an alternative aTNF or start treatment from a different class of drugs, such as rituximab (RTX). It remains unclear in which clinical settings these therapeutic strategies offer most benefit.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Rheumatologie
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Rheumatologie
UniBasel Contributors:Walker, Ulrich A.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:British Medical Association
ISSN:0003-4967
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:21 Jun 2013 12:29
Deposited On:21 Jun 2013 12:28

Repository Staff Only: item control page